Company announces positive topline results from phase 3 study of single-dose secnidazole (Solosec) for the treatment of trichomoniasis

Study demonstrated a clinically and statistically significant response rate, or microbiological cure, in patients dosed with secnidazole versus placebo (p<0.001). UK and EU developmental status is currently unknown.

Biospace Inc.